Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 240 clinical trials
First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer

metastatic non-small cell lung cancer (NSCLC) who have not previously treated with an epidermal growth factor tyrosine kinase inhibitor agent.

osimertinib
brain metastases
EGFR
stage iv non-small cell lung cancer
metastasis
  • 1 views
  • 24 Jan, 2021
  • 11 locations
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

kinase inhibitor midostaurin to standard chemotherapy prolongs event-free survival (EFS) and overall survival (OS) in patients with a FLT3 mutation. Gilteritinib is a more potent and more specific

blast cells
consolidation therapy
tyrosine
serum bilirubin level
hematologic disorder
  • 10 views
  • 23 Jan, 2021
  • 1 location
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

leukemia (CLL). Participants will be enrolled into 3 cohorts: treatment-naive (TN), relapsed/refractory (R/R), and prior Bruton tyrosine kinase inhibitor (BTKi) therapy. Participants will remain on study

anemia
lymphadenopathy
fever
chronic lymphocytic leukemia
acalabrutinib
  • 275 views
  • 19 Feb, 2021
  • 156 locations
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

(EGFR). Osimertinib is an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the

osimertinib
non-squamous non-small cell lung cancer
kinase inhibitor
recurrent non-small cell lung cancer
stage iv non-small cell lung cancer
  • 811 views
  • 27 Jan, 2021
  • 167 locations
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM)

) in symptomatic and anemic subjects who have previously received an approved Janus kinase inhibitor (JAKi) therapy for myelofibrosis (MF). The purpose of this clinical study is to compare the

anemia
thrombocytosis
direct bilirubin
conjugated bilirubin
thrombocytopenia
  • 249 views
  • 24 Feb, 2021
  • 223 locations
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

gilbert's syndrome
neutrophil count
obinutuzumab
chronic lymphocytic leukemia
lymphoid leukemia
  • 0 views
  • 03 Feb, 2021
  • 13 locations
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).

growth factor
measurable disease
non-squamous non-small cell lung cancer
EGFR
carboplatin
  • 74 views
  • 30 Jan, 2021
  • 79 locations
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK ROS1 OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations …

tyrosine
measurable disease
ROS1
lymphoma
cancer
  • 0 views
  • 03 Feb, 2021
  • 25 locations
A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed or refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in …

imatinib
tyrosine
dasatinib
nilotinib
  • 106 views
  • 30 Jan, 2021
  • 18 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

tumor markers
radiopharmaceutical
brainstem tumor
blood transfusion
alpha-fetoprotein
  • 990 views
  • 14 Feb, 2021
  • 113 locations